CN114126711A - 药物和使用所述药物治疗或预防糖尿病并发症的方法 - Google Patents

药物和使用所述药物治疗或预防糖尿病并发症的方法 Download PDF

Info

Publication number
CN114126711A
CN114126711A CN202080035808.7A CN202080035808A CN114126711A CN 114126711 A CN114126711 A CN 114126711A CN 202080035808 A CN202080035808 A CN 202080035808A CN 114126711 A CN114126711 A CN 114126711A
Authority
CN
China
Prior art keywords
group
formula
smtp
week
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080035808.7A
Other languages
English (en)
Chinese (zh)
Inventor
柴田佳太
篠内良介
桥本光正
野部浩司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Massachusetts Co ltd
Showa University
Original Assignee
Tms KK
Showa University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tms KK, Showa University filed Critical Tms KK
Publication of CN114126711A publication Critical patent/CN114126711A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080035808.7A 2019-03-12 2020-03-12 药物和使用所述药物治疗或预防糖尿病并发症的方法 Pending CN114126711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-044670 2019-03-12
JP2019044670 2019-03-12
PCT/JP2020/010967 WO2020184691A1 (ja) 2019-03-12 2020-03-12 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法

Publications (1)

Publication Number Publication Date
CN114126711A true CN114126711A (zh) 2022-03-01

Family

ID=72426033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035808.7A Pending CN114126711A (zh) 2019-03-12 2020-03-12 药物和使用所述药物治疗或预防糖尿病并发症的方法

Country Status (15)

Country Link
US (1) US20220218664A1 (https=)
EP (1) EP3939659A4 (https=)
JP (1) JPWO2020184691A1 (https=)
KR (1) KR20220009371A (https=)
CN (1) CN114126711A (https=)
AU (1) AU2020238177A1 (https=)
BR (1) BR112021018084A8 (https=)
CA (1) CA3133204A1 (https=)
CL (1) CL2021002373A1 (https=)
EA (1) EA202192483A1 (https=)
IL (1) IL286289A (https=)
MX (1) MX2021011007A (https=)
PE (1) PE20220333A1 (https=)
SG (1) SG11202109982YA (https=)
WO (1) WO2020184691A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
WO2022171151A1 (zh) * 2021-02-10 2022-08-18 上海森辉医药有限公司 一种smtp-7衍生物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224738A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 血管新生関連疾患の予防又は治療用医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05176782A (ja) * 1992-01-08 1993-07-20 Taisho Pharmaceut Co Ltd Ｎｇｆ作用増強因子
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
US20090270476A1 (en) 2005-10-06 2009-10-29 Keiji Hasumi Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof
EP2000540B1 (en) 2006-03-27 2014-05-14 Tokyo University of Agriculture and Technology Tlo Co., Ltd. Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer
WO2010110026A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東京農工大学 メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物
WO2011004620A1 (ja) * 2009-07-06 2011-01-13 国立大学法人東京農工大学 細胞保護剤
WO2011125930A1 (ja) * 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
JP5952257B2 (ja) * 2011-02-24 2016-07-13 株式会社ティムス 可溶性エポキシドハイドロラーゼ阻害剤
JP2019044670A (ja) 2017-08-31 2019-03-22 スズキ株式会社 内燃機関の排出ガス浄化システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224738A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 血管新生関連疾患の予防又は治療用医薬組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A multimodal disease modifying approach to treat neuropathic pain-inhibition of soluble epoxide hydrolase (sEH)", 《DRUG DISCOVERY TODAY》, vol. 20, no. 11, pages 1382 - 1390 *
MATSUMOTO等: "Soluble Epoxide Hydrolase as an Anti-inflammatory Target of the Thrombolytic Stroke Drug SMTP-7", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 289, no. 52, pages 35826 - 35838 *
SHIBATA等: "Evaluation of the effects of a new series of SMTPs in the acetic acid-induced embolic cerebral infarct mouse model", 《EUROPEAN JOURNAL OF PHARMACOLOGY》, vol. 818, pages 221 - 227, XP085313014, DOI: 10.1016/j.ejphar.2017.10.055 *
徐继周: "抗炎与免疫调节在糖尿病肾病治疗中的作用研究", 《世界最新医学信息文摘》, vol. 16, no. 20, pages 58 - 59 *

Also Published As

Publication number Publication date
JPWO2020184691A1 (https=) 2020-09-17
EP3939659A4 (en) 2022-12-21
WO2020184691A1 (ja) 2020-09-17
KR20220009371A (ko) 2022-01-24
EA202192483A1 (ru) 2021-12-24
MX2021011007A (es) 2022-03-11
CA3133204A1 (en) 2020-09-17
IL286289A (en) 2021-10-31
US20220218664A1 (en) 2022-07-14
PE20220333A1 (es) 2022-03-14
SG11202109982YA (en) 2021-10-28
BR112021018084A2 (https=) 2021-12-21
BR112021018084A8 (pt) 2022-10-04
EP3939659A1 (en) 2022-01-19
CL2021002373A1 (es) 2022-06-17
AU2020238177A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
TW201639564A (zh) 胰腺炎治療
KR20110053347A (ko) 탈라세미아를 치료하는 방법
AU2011230081A1 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
US20140094490A1 (en) Anti-neurodegenerative disease agent
CN121695155A (zh) 减少与甲状腺相关的副作用的方法
CN114126711A (zh) 药物和使用所述药物治疗或预防糖尿病并发症的方法
US20260053766A1 (en) (s)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (apl) for use in the treatment of non-alcoholic steatohepatitis (nash), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis
WO2008008650A1 (en) Methods for treating cystic kidney diseases
US12377095B2 (en) Use of ligustrazine nitrone derivatives in treatment and prevention of diabetic complication diseases
Althubiti Tyrosine kinase targeting: a potential therapeutic strategy for diabetes
US20220079895A1 (en) Composition for preventing or treating liver diseases
JP2010531854A5 (https=)
TWI472519B (zh) 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
KR20140085580A (ko) p38을 억제하기 위한 약물 및 이의 적용
KR20080111021A (ko) 철 대사 장애의 치료를 위한 스트로빌루린의 용도
CN103108634B (zh) 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
JP7356113B2 (ja) 薬剤及び該薬剤を用いて腎臓病を治療又は予防する方法
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
US10745429B2 (en) Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
CA3074736A1 (en) Gamma-ketoaldehyde scavengers for treating liver fibrosis
CN116003290B (zh) 一种3-苯基戊二酸衍生物lonp1激活剂及其在慢性肾脏病防治药物中的应用
US20210369664A1 (en) Prophylactic or therapeutic agent for pulmonary hypertension which comprises ppar? agonist
KR20250123035A (ko) 섬유증과 간질환 치료의 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220915

Address after: Tokyo

Applicant after: Showa University

Applicant after: Bojian Massachusetts Co.,Ltd.

Address before: Tokyo

Applicant before: Showa University

Applicant before: TMS Kabushiki Kaisha

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301

WD01 Invention patent application deemed withdrawn after publication